EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Multinational, multicenter, retrospective cohort study assessing treatment patterns and outcomes in solid organ transplant recipients considered refractory, resistant, or intolerant to anti-CMV therapies

Paolo Antonio Grossi, Judith Kahn, Sara Belga, Merel Hellemons, Ilaria Albieri, François Gavini, Tien Bo, Irmgard Andresen, Luca Toti

Frontiers in Transplantation · 19.11.2026 · 5

DOI: 10.3389/frtra.2026.1867958 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Frontiers in Transplantation, online erschienen am 19.11.2026. Verfasst von Paolo Antonio Grossi und 8 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Real-world evidence on cytomegalovirus (CMV) infection after solid organ transplant (SOT) is limited, particularly with refractory, resistance, and/or intolerance to anti-CMV agents (RRI).

Methods

This retrospective chart review study across 15 transplant centers in Canada, Israel, and Europe included adult SOT recipients with RRI CMV infection.

Results

Overall, patients ( N = 109) experienced 169 CMV episodes, with a median (Q1–Q3) time from SOT to the first CMV episode of 119 days (46–231) and from SOT to RRI diagnosis of 187 (100–296) days. CMV clearance during the first RRI CMV episode was achieved by 83 patients (76.1%) (median time to clearance: 48 days from the start of the index episode, 32 days from RRI diagnosis). Recurrent CMV episodes occurred in 30.3% of patients ( n = 33; median time to recurrence from the end of the index episode, 42 days). In total, 70 patients (64.2%) experienced myelosuppression and 16 (14.7%) experienced nephrotoxicity. Overall, 26 patients (23.9%) experienced organ rejection and 6.4% ( n = 7) graft loss after RRI diagnosis. Overall, 28 patients (25.7%) died following SOT.

Conclusion

Post-SOT RRI CMV infection may lead to high treatment burden and negatively affect outcomes. There is a need for anti-CMV therapies that can achieve CMV clearance without treatment-limiting toxicities.

Zitieren

APA

Grossi, P. A., Kahn, J., Belga, S., Hellemons, M., Albieri, I., Gavini, F., Bo, T., Andresen, I., & Toti, L. (2026). Multinational, multicenter, retrospective cohort study assessing treatment patterns and outcomes in solid organ transplant recipients considered refractory, resistant, or intolerant to anti-CMV therapies. Frontiers in Transplantation, 5. https://doi.org/10.3389/frtra.2026.1867958

Vancouver

Grossi PA, Kahn J, Belga S, Hellemons M, Albieri I, Gavini F, et al. Multinational, multicenter, retrospective cohort study assessing treatment patterns and outcomes in solid organ transplant recipients considered refractory, resistant, or intolerant to anti-CMV therapies. Frontiers in Transplantation. 2026;5. doi:10.3389/frtra.2026.1867958

BibTeX
@article{Grossi2026,
  author = {Grossi, Paolo Antonio and Kahn, Judith and Belga, Sara and Hellemons, Merel and Albieri, Ilaria and Gavini, François and Bo, Tien and Andresen, Irmgard and Toti, Luca},
  title = {Multinational, multicenter, retrospective cohort study assessing treatment patterns and outcomes in solid organ transplant recipients considered refractory, resistant, or intolerant to anti-CMV therapies},
  journal = {Frontiers in Transplantation},
  year = {2026},
  volume = {5},
  doi = {10.3389/frtra.2026.1867958}
}
Kostenlos starten →